Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 70 years old with certain blood cancers or bone marrow disorders, including specific types of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), mixed-type acute leukemia, chronic myelogenous leukemia (CML) in a second chronic phase, chronic myelomonocytic leukemia (CMML), or relapsed/refractory Hodgkin's lymphoma — each with specific disease stage requirements (confirm with trial site).
• People who do not have a suitable matched donor available (related or unrelated) for a stem cell transplant.
• People for whom at least two cord blood units are available that meet specific cell count and tissue-matching requirements, plus at least one backup cord blood unit.
• People who are well enough to function at a certain level of physical ability — scored at 80 or above on a standard health scale for one treatment regimen, or above 60 for another (confirm with trial site).
• People who have been in remission in the central nervous system (brain and spinal fluid) at the time of joining, if there was a history of cancer spreading there.
• People who are able to understand and willing to sign a written consent form.
• Women who could potentially become pregnant must agree to use highly effective contraception (with a failure rate of less than 1% per year) or remain abstinent during treatment and for 12 months after the last dose of a study medication called abatacept.
• Men must agree to use a condom plus an additional highly effective contraceptive method, or remain abstinent, during treatment and for 12 months after the last dose of abatacept, and must agree not to donate sperm during this time.

Who may not be able to join:

• People whose kidneys, liver, lungs, or heart are not functioning well enough — including poor kidney filtration, elevated liver enzymes or bilirubin levels, reduced lung capacity, or a weakened heart pump function (confirm specific thresholds with trial site).
• People with uncontrolled or active infections, uncontrolled heart failure, unstable chest pain, irregular heart rhythms, or mental health or personal circumstances that would make it difficult to follow the study requirements.
• Women who are pregnant or breastfeeding, due to the significant risks the chemotherapy used in this trial poses to a developing baby.
• People with any other condition that, in the treating doctor's judgement, would interfere with safe participation in the trial or make study results difficult to interpret.
• People with known allergies or intolerances to any of the medications used in this study.
• People whose immune system has developed specific antibodies against the cord blood unit intended for their transplant.
• People with a transplant-related health burden score greater than 5 on a standard medical assessment tool (the HCT-CI).
• People who have had a stem cell transplant (either their own cells or a donor's) within the past 12 months.

Important: Always verify eligibility with the trial site directly before applying.